Treatment
Empagliflozin clinical trials
We’re tracking 82 recruiting studies that include Empagliflozin, each written for real people, not researchers, below.
Recruiting studies
- NCT07038356RecruitingPhase 3
Continuing empagliflozin during heart failure hospitalizations
This study tests whether continuing empagliflozin (a heart failure medicine) during a hospital stay for heart failure is beneficial compared to stopping it. Participation may help improve recovery and reduce complications.
Jena, ThuringiaAges 18 years+ - NCT06992440RecruitingPhase 2
Empagliflozin for better right heart function in pulmonary hypertension
This trial tests if a diabetes drug can help people with pulmonary arterial hypertension whose right heart function is reduced. Participants take empagliflozin or a placebo for 24 weeks to see if heart function improves.
Baltimore, MarylandAges 18 years+ - NCT06955260RecruitingPhase 3
Empagliflozin for Fontan circulatory failure
This trial tests if a diabetes medicine called empagliflozin can help people with Fontan circulatory failure feel better and do more of their daily activities.
Vancouver, British ColumbiaAges 18 years+ - NCT06935370RecruitingPhase 3
Testing vicadrostat with empagliflozin for heart failure with weak pump
This trial tests a new drug called vicadrostat combined with another drug, empagliflozin, for people with heart failure and a weak heart pump. It aims to see if this combination helps improve symptoms and outcomes.
Beverly Hills, CaliforniaAges 18 years+ - NCT05879276RecruitingPhase 3
Early empagliflozin for shock patients after ICU start
This trial studies whether starting empagliflozin early in adults with cardiogenic shock helps people live longer and have fewer hospital returns, while also checking heart pumping and kidney function. It may help some ICU patients, but eligibility is strict and depends on kidney function and prior medication use.
Ars-LaquenexyAges 18 years+ - NCT06862739RecruitingPhase 4
Testing a 3-drug combination for better blood sugar control
This study tests a combination of three diabetes medicines (empagliflozin, linagliptin, and metformin) to see if it helps control blood sugar in people with type 2 diabetes. It may be an option if your current treatment isn't working well enough.
Faisalabad, Punjab ProvinceAges 18–80 - NCT05610956RecruitingEarly Phase 1
Empagliflozin for mild-to-moderate ulcerative colitis
This early trial studies whether empagliflozin can improve ulcerative colitis symptoms and is safe for people with mild to moderate disease. If it works, it may reduce ongoing colon inflammation and help people feel better.
TantaAges 18–70 - NCT06729996RecruitingPhase 2
Comparing two diabetes medicines for pancreatitis-related diabetes
This trial tests whether pioglitazone or empagliflozin is better at managing diabetes caused by chronic or recurrent pancreatitis. You will take one of these pills daily for 6 months and track your blood sugar and ketones at home. The goal is to find a safer, more effective treatment for this type of diabetes.
Rochester, MinnesotaAges 18–80 - NCT06483074RecruitingPhase 2
Empagliflozin to preserve kidney function in new peritoneal dialysis patients
This trial tests whether empagliflozin, a medication originally for diabetes, can help protect the remaining kidney function in people who have just started peritoneal dialysis. If you started dialysis within the last 3 months and still make some urine, this study may be a good fit.
Hong KongAges 18–75 - NCT06653738RecruitingPhase 3
Testing empagliflozin and diet advice for kidney stone prevention
This trial tests if a medication called empagliflozin, combined with personalized diet advice, can help prevent kidney stones from coming back. It may be an option if you've had two or more kidney stone events in the last 10 years and your stones were mostly calcium-based.
AmiensAges 18 years+ - NCT06642272RecruitingPhase 4
Comparing two diabetes drugs in real-world use
This trial compares two common diabetes medications, empagliflozin and dapagliflozin, to see which works better in everyday practice. It aims to find the best treatment option for patients with type 2 diabetes.
CopenhagenAges 18 years+ - NCT06554301RecruitingPhase 1
Empagliflozin for pulmonary arterial hypertension study
This study tests if the diabetes drug empagliflozin can help people with pulmonary arterial hypertension (PAH), a condition causing high blood pressure in the lungs. It aims to see if the drug improves symptoms and is safe for patients with moderate symptoms.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06507657RecruitingEarly Phase 1
Empagliflozin for heart health in older adults
This study tests whether a medication called empagliflozin (a diabetes drug) can improve heart function in older adults with high blood pressure and obesity who are at risk for heart failure but do not have it yet. You would take the pill daily and have heart ultrasounds to check your heart's health.
Minneapolis, MinnesotaAges 60 years+ - NCT06506422RecruitingPhase 2/Phase 3
How empagliflozin may help aging arteries
This study tests if a diabetes medication, empagliflozin, can reduce age-related stiffening of arteries in people without diabetes. If you are between 60 and 80 and have stiff arteries, this trial could help improve your vascular health.
Columbia, MissouriAges 60–80 - NCT06424288RecruitingPhase 3
Testing vicadrostat plus empagliflozin for heart failure
This study tests whether adding a new study drug called vicadrostat to the standard heart failure medicine empagliflozin helps people with heart failure. It may be a good option if you have heart failure with preserved pumping function and are not already on a medicine called an MRA.
Mobile, AlabamaAges 18 years+ - NCT06110130RecruitingPhase 4
Empagliflozin for kidney health in African American veterans
This study is testing whether the drug empagliflozin (Jardiance) can help protect the kidneys of African American veterans who already have some kidney damage but do not have diabetes. The goal is to see if the drug can reduce damage at the cellular level.
Washington D.C., District of ColumbiaAges 19–90 - NCT06013865RecruitingPhase 4
Empagliflozin for kidney transplant recipients
This trial tests if empagliflozin, a diabetes medicine that also protects the kidneys, can help people who have received a kidney transplant. It may be an option if you have reduced kidney function or diabetes after transplant.
Hines, IllinoisAges 19 years+ - NCT05786443RecruitingPhase 2
Empagliflozin test in adults on regular dialysis
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
Boston, MassachusettsAges 18 years+ - NCT05726032RecruitingPhase 2
Empagliflozin for fluid buildup from cirrhosis
This Phase 2 study tests empagliflozin to see if it can improve fluid buildup (ascites) in people with cirrhosis. It may help reduce symptoms related to fluid retention, but you must meet specific safety and stability requirements.
New Haven, ConnecticutAges 18 years+ - NCT04602754RecruitingPhase 3
Oral treatment test for type 2 diabetes and bad cholesterol
This Phase 3 study tests whether Berlim 25/20 can improve blood sugar control and cholesterol (LDL) in adults with type 2 diabetes who haven’t met targets despite prior lifestyle guidance and treatment. It also looks at safety, including effects on the heart and medication-related side effects.
Campinas, São PauloAges 18–85 - NCT05028140RecruitingPhase 3
Testing a lifestyle-and-diet program for type 2 diabetes control
This Phase 3 study tests whether a program run by the Piemonte Association can improve blood sugar control in people with type 2 diabetes who haven’t reached their target after usual diet, exercise, and stable medicines. It also aims to check that the approach is safe for participants.
Hortolândia, São PauloAges 18–85 - NCT04670666RecruitingPhase 3
Study of Madalena for type 2 diabetes not controlled
This Phase 3 study tests Madalena to improve blood sugar control in adults with type 2 diabetes that hasn’t met targets despite diet, exercise, and diabetes medicines. You may join if your recent blood sugar tests and body size fall within specific ranges and you don’t have key medical exclusions.
Hortolândia, São PauloAges 18 years+ - NCT05669742RecruitingPhase 3
Empagliflozin plus olanzapine to reduce metabolic side effects
This trial tests whether adding empagliflozin to standard olanzapine treatment can improve metabolic problems (like blood sugar and cholesterol changes) that can happen with olanzapine in people with schizophrenia. If you qualify, you would be closely monitored for benefits and side effects.
TantaAges 18–65 - NCT05164263RecruitingPhase 4
Testing empagliflozin for adults with type 2 diabetes on tablets
This study looks at how well and how safely empagliflozin works in real-world care for adults with type 2 diabetes who are not controlled on current pill treatment. Some participants take it with metformin, and the study helps confirm what to expect in everyday patients.
Kabul, AfghanistanAges 18–65
Common questions
- Are there clinical trials studying Empagliflozin?
- Yes. Clin2 currently lists 82 recruiting studies that include Empagliflozin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Empagliflozin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Empagliflozin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Empagliflozin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.